Research AboutOfferDocumentationLoginBook a demo
ResearchAboutOfferLoginBook a demo

Inatherys

Ownership
Private
Employees
~10
Therapeutic Areas
OncologyImmunology
Stage
Phase 1
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
monoclonal antibodies (mAbs)antibody-drug conjugates (ADC)

Inatherys General Information

Inatherys has developed several monoclonal antibodies targeting cancer and inflammation. Their lead programs have demonstrated effectiveness in preclinical studies and are being prepared for clinical development in patients with advanced disease where traditional treatments have failed

Contact Information

Website
https://www.inatherys.com/
Primary Industry
Biotech
Corporate Office
Évry-Courcouronnes, Île-de-France
France

Drug Pipeline

INA03
Phase 1
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Inatherys's pipeline data

Book a demo

Key Partnerships

Partnership with Adult Hematology Department of Necker Hospital, Paris

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Inatherys Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Inatherys's complete valuation and funding history, request access »

Inatherys Financial Metrics

See full profile
Book a demo
OverviewDrug PipelineTechnologiesPartnershipsFundingCompetitorsAnalysisPatentsLicensing Deals